公开(公告)号：US20230181482A1

公开(公告)日：2023-06-15

申请号：US18056367

申请日：2022-11-17

申请人： AstraZeneca AB

发明人： Martin HEMMERLING ,  Werngard CZECHTIZKY ,  David ULKOSKI ,  Aditya Ravindra POTE ,  Lennart LINDFORS

IPC分类号： A61K9/51 ,  A61K48/00 ,  C07D305/14 ,  C07D309/14 ,  C07D307/14 ,  C07D309/04 ,  C07D305/06 ,  C07D319/12 ,  C07D311/96 ,  C07D307/94

CPC分类号： A61K9/5123 ,  A61K9/5146 ,  A61K48/0033 ,  C07D305/14 ,  C07D309/14 ,  C07D307/14 ,  C07D309/04 ,  C07D305/06 ,  C07D319/12 ,  C07D311/96 ,  C07D307/94

摘要： Disclosed herein are compounds of Formula (I), Formula (III) or Formula (IIIa), or pharmaceutically acceptable salts thereof, wherein A, L, X1, X2, a, b, R1 and R2 are as defined herein. Also disclosed are lipid nanoparticles comprising a compound of Formula (I), Formula (III) or Formula (IIIa), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising a compound of Formula (I), Formula (III) or Formula (IIIa), or a pharmaceutically acceptable salt thereof and a nucleic acid segment; as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising a compound of Formula (I), Formula (III) or Formula (IIIa), or a pharmaceutically acceptable salt thereof, and a nucleic acid segment.